Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant

NCT03697395 · View on ClinicalTrials.gov ↗

Study Summary

Chronic allograft rejection of the transplanted lung (CLAD) is a major health issue in patients after lung transplant. This study is a registry-forming study with concurrent tissue banking from surveillance bronchoscopy in addition to extra tissue sampling of blood and urine. Patients will be characterized by usual clinical phenotyping and the latest imaging methods so that diseased condition underlying CLAD can be better understood.

Interventions

  • DIAGNOSTIC_TEST Lung transplant recipient without MRI imaging
  • DRUG Lung transplant recipient with MRI imaging

Study Locations (1)

Virginia

  • University of Virginia Health System — Charlottesville

Trial Details

FieldValue
Enrollment Target 1,200 participants
Start Date 2019-04-01
Est. Completion 2038-12-31
Phase Phase 2

Sponsor

University of Virginia

392 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03697395

The ClinicalTrials.gov registry entry for NCT03697395 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 392 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Chronic Rejection of Lung Transplant appearing as the primary indexed condition, and to 2 interventions — of which Lung transplant recipient without MRI imaging is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03697395 reports 1 study location spanning 1 distinct geographic area — top geographies include Virginia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03697395 about?

NCT03697395 is a clinical study titled "Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant". Chronic allograft rejection of the transplanted lung (CLAD) is a major health issue in patients after lung transplant. This study is a registry-forming study with concurrent tissue banking from surveillance bronchoscopy in addition to extra tissue sampling of blood and urine. Patients will be charac...

What is the current status of trial NCT03697395?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,200 participants. The study started on 2019-04-01. Estimated completion is 2038-12-31.

What conditions does trial NCT03697395 study?

This clinical trial studies the following conditions: Chronic Rejection of Lung Transplant. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03697395?

The interventions under investigation include: Lung transplant recipient without MRI imaging (DIAGNOSTIC_TEST), Lung transplant recipient with MRI imaging (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03697395?

This trial is sponsored by University of Virginia, which has 392 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03697395 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial